The co-expression of CD166 and CD133 ranged from 0.19% to 53.6% (median 1.2%) and the co-expression of CD44 and CD166 ranged from 54% to 96.55% (median 86.6%) in the examined tumor tissue cell samples. Here, ALCAM is linked to neoplasm.